Pharma Journalist -

Telix announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting…
Read More...

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announced the close of a €129 million ($138…
Read More...

Valneva SE, a specialty vaccine company, announced that the U.S. Food and Drug Administration (FDA) has approved IXCHIQ, Valneva’s single-dose, live-attenuated vaccine indicated for the…
Read More...

AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric…
Read More...

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of…
Read More...

OrsoBio, Inc. announced the successful completion of a $60 million Series A financing, bringing the total capital raised by the Company to $97 million. The financing, which will support…
Read More...

Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced $40 million in Series A extension funding committed by Apple Tree Partners…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who…
Read More...

The three-day agenda for the 6th Chronic Kidney Disease (CKD) Drug development Summit has been announced. Taking place March 19-21, 2024 in Boston, M.A., this year’s program features…
Read More...